[Epiafzelechin-(4beta->8)]2-4\'-O-methyl-epigallocatechin



Compound IDCDAMM01790
Common name[Epiafzelechin-(4beta->8)]2-4\'-O-methyl-epigallocatechin
IUPAC name4-[2-(3,5-dihydroxy-4-methoxyphenyl)-3,5,7-trihydroxy-3,4-dihydro-2H-chromen-8-yl]-2-(4-hydroxyphenyl)-8-[3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-4-yl]-3,4-dihydro-2H-chromene-3,5,7-triol
Molecular formulaC46H40O17

Experimental data

Retention time3.2
Adduct[M+H]+
Actual mz865.235
Theoretical mz865.234
Error1.18
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.4916

Identifiers and class information

Inchi keyQKCQZHCKCYRFJX-UZWUUNAJNA-N
SmilesOC1=CC=C(C=C1)C2OC=3C=C(O)C=C(O)C3C(C4=C(O)C=C(O)C5=C4OC(C6=CC=C(O)C=C6)C(O)C5C=7C(O)=CC(O)=C8C7OC(C9=CC(O)=C(OC)C(O)=C9)C(O)C8)C2O
SuperclassPhenylpropanoids and polyketides
ClassFlavonoids

Pharmacokinetic properties

Number of descriptor values(#stars)11
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)14
Number of reactive functional groups (#rtvFG)0
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)864.812
Computed dipole moment(dipole)7.138
Total solvent accessible surface area (SASA)1048.98
Hydrophobic component of SASA (FOSA)185.788
Hydrophilic component of SASA (FISA)477.449
Pie component of the SASA (PISA)385.748
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)2194.26
Number of hydrogen bond donors (donorHB)13
Number of hydrogen bond acceptors (accptHB)15.6
Free energy of solvation of dipole (dip^2/V)0.0232233
Index of cohesive interaction in solids (ACxDN^.5/SA)0.05362
Globularity descriptor (glob)0.778491
Predicted polarizability in cubic angstroms (QPpolrz)76.355
Predicted hexadecane/gas partition coefficient (QPlogPC16)27.302
Predicted octanol/gas partition coefficient (QPlogPoct)55.417
Predicted water/gas partition coefficient (QPlogPw)39.433
Predicted octanol/water partition coefficient (QPlogPo/w)1.64
Predicted aqueous solubility (QPlogS)-5.787
Conformation-independent predicted aqueous solubility (CIQPlogS)-11.413
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-6.956
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)0.294
Predicted brain/blood partition coefficient (QPlogBB)-5.532
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)0.075
Predicted skin permeability, log Kp (QPlogKp)-7.616
PM3 calculated ionization potential (IP(ev))8.511
PM3 calculated electron affinity (EA(eV))0.164
Number of likely metabolic reactions (#metab)20
Prediction of binding to human serum albumin (QPlogKhsa)0.143
Predicted qualitative human oral absorption (HumanOralAbsorption)1
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)0
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)293.012
Number of nitrogen and oxygen atoms (#NandO)17
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)3

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P22748CA4Carbonic anhydrase IVT53378SEA
Q92731ESR2Estrogen receptor betaT80896SEA
P08253MMP2Matrix metalloproteinase 2T68251SwissTargetPrediction
P14780MMP9Matrix metalloproteinase 9T54156SwissTargetPrediction
P03372ESR1Estrogen receptor alphaT02506SEA
P20151KLK2Kallikrein 2T01908SEA
P15692VEGFAVascular endothelial growth factor AT20761SEA
P49763PGFPlacenta growth factorT70792SEA
P14679TYRTyrosinaseT97035SEA
P52209PGD6-phosphogluconate dehydrogenaseT76497SEA
Q16678CYP1B1Cytochrome P450 1B1T92521SEA
P16152CBR1Carbonyl reductase [NADPH] 1T70518SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T53378DI0046Bacterial infection[ICD-11: 1A00-1C4Z]P22748CA4
T53378DI0166Glaucoma[ICD-11: 9C61]P22748CA4
T53378DI0372Seborrhoeic dermatitis[ICD-11: EA81]P22748CA4
T80896DI0062Breast cancer[ICD-11: 2C60-2C6Y]Q92731ESR2
T80896DI0108Cushing syndrome[ICD-11: 5A70]Q92731ESR2
T80896DI0254Menopausal disorder[ICD-11: GA30]Q92731ESR2
T80896DI0432Vasomotor/allergic rhinitis[ICD-11: CA08]Q92731ESR2
T68251DI0238Lung cancer[ICD-11: 2C25]P08253MMP2
T54156DI0219Ischaemic/haemorrhagic stroke[ICD-11: 8B20]P14780MMP9
T54156DI0391Solid tumour/cancer[ICD-11: 2A00-2F9Z]P14780MMP9
T54156DI0395Stomach cancer[ICD-11: 2B72]P14780MMP9
T54156DI0419Ulcerative colitis[ICD-11: DD71]P14780MMP9
T02506DI0106COVID-19[ICD-11: 1D6Y]P03372ESR1
T01908DI0213Innate/adaptive immunodeficiency[ICD-11: 4A00]P20151KLK2
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T70792DI0095Colorectal cancer[ICD-11: 2B91]P49763PGF
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T76497DI0337Pituitary gland disorder[ICD-11: 5A60-5A61]P52209PGD
T70518DI0037Asthma[ICD-11: CA23]P16152CBR1

Copyright © 2025